Skip to content
Menu

Citizens Reiterates Market Outperform on Acrivon Therapeutics, Maintains $13 Price Target

Benzinga Newsdesk 15 hours ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citizens analyst Silvan Turkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $13 price target.

Citizens analyst Silvan Turkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $13 price target.

Read at benzinga.com